CLOs on the Move

Rapid Pathogen Screening

www.rpsdetectors.com

 
Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cullgen

Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.

Arcus Biosciences

Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world`s largest biotechnology research hub.

NICO

NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.

AMAG Pharmaceuticals

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Headquartered in Waltham, Massachusetts, we work to develop and deliver important therapeutics, conduct clinical research in areas of unmet need and create education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Geneos Therapeutics

Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.